To include your compound in the COVID-19 Resource Center, submit it here.

BIIB's rFIXFc meets Phase III endpoints

Biogen Idec Inc. (NASDAQ:BIIB) and partner Swedish Orphan Biovitrum AB (SSE:SOBI) said rFIXFc as prophylaxis met the primary efficacy and safety endpoints in the Phase III B-LONG trial to treat hemophilia

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE